Welcome to my New Blog... Graphs Tables for Skin Cancer

Skin Cancer, mesothelioma, Mesothelioma Cancer, Mesothelioma Lwayer
=======================================================

Friday, March 14, 2008

Fw: Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes.



----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:59 PM
Subject: Unusual Features of Malignant Pleural Mesothelioma Metastatic to the Mediastinal Lymph Nodes.

[1]Appl Immunohistochem Mol Morphol. 2008 Feb 8;
Wagner D, Bourne PA, Yang Q, Goldman BI, Lewis JS, Xu H

Malignant pleural mesothelioma (MPM) is a rare cancer that metastasizes to mediastinal lymph nodes (MLNs). The diagnosis of MPM metastatic to MLNs may not be straightforward. We describe 3 cases to highlight unusual entities of MPM metastatic to MLNs as follows. One patient with a history of T3N1M0, poorly differentiated esophageal adenocarcinoma and malignant melanoma presented with shortness of breath, mediastinal lymphadenopathy, and pleural effusion; metastatic disease was clinically suspected. Unexpectedly, immunohistochemical studies supported the diagnosis of MPM metastatic to the MLN on biopsy. In another case, mesothelial cell inclusions were initially diagnosed based on the light microscopy, immunohistochemistry, and lack of pleural thickening on computed tomography studies. Subsequent fine needle aspiration of an enlarged cervical lymph node found an atypical mesothelial proliferation, and metastatic mesothelioma was strongly suspected. Video-assisted thoracoscopic examination showed small visceral nodules, and pleural biopsy was diagnosed as malignant epithelioid mesothelioma. The mediastinal and cervical lymph node biopsies were reinterpreted as positive for MPM. In the last case, MLN biopsy showed a malignant epithelioid cell proliferation. Calretinin, CK5/6, WT-1, D2-40, p63, and CD5 were immunohistochemically detected in the tumor but epithelial markers and TTF-1 were negative. Metastatic mesothelioma was considered based on immunohistochemistry and computerized tomography finding of pleural thickening even though p63 and CD5 positivity were unusual. In summary, MPM may present as mediastinal lymphadenopathy with metastases or it may be a concurrent neoplasm with other malignancies or shows an unusual immunohistochemical staining pattern. Caution should be used when diagnosing mesothelial cell inclusions in MLNs.



___
Source: http://www.hubmed.org/display.cgi?uids=18301236
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 


Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fw: eComment: EPP and P/D: which to choose?



----- Forwarded Message ----
From: HubMed - mesothelioma <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:59 PM
Subject: eComment: EPP and P/D: which to choose?

[1]Interact Cardiovasc Thorac Surg. 2008 Feb; 7(1): 106
Hasegawa S





___
Source: http://www.hubmed.org/display.cgi?uids=18234774
--
 Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 



Looking for last minute shopping deals? Find them fast with Yahoo! Search.

Fw: [New diagnostic markers for malignant pleural mesothelioma.]



----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:59 PM
Subject: [New diagnostic markers for malignant pleural mesothelioma.]

[1]Bull Cancer. 2008 Feb 28; 95(2): 177-184
Grigoriu BD, Grégoire M, Chahine B, Scherpereel A

The increasing number of malignant pleural mesothelioma (MPM) is a serious public health problem. The prognosis of this tumor is poor and most of the patients are diagnosed late in the disease's course when curative treatment is no more an option. It is therefore necessary to diagnose earlier MPM in these patients in order to obtain a potential significant improvement in survival. Some serum markers have been previously proposed for MPM diagnosis but none had sufficient sensitivity and specificity for being use in routine. Recently, soluble mesothelin and osteopontin have been proposed as diagnostic markers for mesothelioma. The authors reviewed recent data concerning the utility of these two molecules in the diagnosis and the treatment of MPM.. Mesothelin seems to be a specific marker for the epithelioid subtype of mesothelioma. Despite a good sensitivity, osteopontin has a low specificity for mesothelioma diagnosis. However, there is not enough data yet to propose guidelines on the use of these markers in a day to day practice.



___
Source: http://www.hubmed.org/display.cgi?uids=18304902
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 



Never miss a thing. Make Yahoo your homepage.

Fw: Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.



----- Forwarded Message ----
From: HubMed - mesothelioma diagnosis <rssfwd@rssfwd.com>
To: shell8377@yahoo.com
Sent: Friday, February 29, 2008 6:57:59 PM
Subject: Local recurrence of tumor at sites of intervention in malignant pleural mesothelioma.

[1]Lung Cancer. 2008 Feb 25;
Metintas M, Ak G, Parspour S, Yildirim H, Erginel S, Alatas F, Batırel HF, Sivrikoz C, Metintas S, Dundar E

In malignant pleural mesothelioma (MPM) patients, local dissemination (LD) of the tumor is frequently observed at the sites of intervention where diagnosis/treatment are performed. We evaluate the factors affecting LD frequency and discuss the use of PR in MPM patients. Histopathologically diagnosed 212 MPM patients who had not received PR were evaulated in terms of development of LD. Of the 212 patients, 29 received supportive therapy, 157 received chemotherapy and 26 received multi-modal therapy. The LD frequency was 13.2% for all patients. The median survival rate was 9 or 10 months in patients with or without LD, respectively. A higher LD frequency was observed in patients receiving thoracotomy. The LD appearance time in supportive care is short. The LD frequency in patients treated with chemotherapy that revealed progressive disease was higher than the patients who revealed stable disease or objective response. LD developed in 2 months in patients with sarcomatous and mixed cell type, and the survival rate was low. LD was not associated with the stage of the disease. The most suitable candidate groups for PR are patients receiving supportive therapy, thoracotomy without multi-modal therapy or patients with sarcomatous and mixed cell type tumors.



___
Source: http://www.hubmed.org/display.cgi?uids=18304688
--
 ~
Powered by [5]RssFwd, a service of [6]Blue Sky Factory, Inc

 


Never miss a thing. Make Yahoo your homepage.